Using ultra-wide-field imaging to assess retinal vein occlusion
Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion
This study is testing how a special imaging technique can help doctors see and understand changes in the eyes of people with retinal vein occlusion to improve their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Renmin Hospital of Wuhan University Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT04075695 on ClinicalTrials.gov |
What this trial studies
This study evaluates the ischemic index and vascular leakage index in patients with retinal vein occlusion using ultra-wide field fluorescein angiography (UWFA). UWFA allows for a broader view of the retina compared to conventional methods, enabling clearer observation of peripheral retinal changes. The study aims to quantitatively analyze these indices and their effects on macular edema and neovascularization associated with retinal vein occlusion. By understanding these changes, the study seeks to improve patient outcomes in managing this condition.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), or hemi-retinal vein occlusion (HRVO) without macular edema.
Not a fit: Patients with other retinal diseases or complications that affect vision may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and management of retinal vein occlusion, potentially leading to better treatment strategies.
How similar studies have performed: While this approach using ultra-wide-field imaging is innovative, similar studies have shown promise in enhancing the understanding of retinal conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female aged 18 years or more 2. Patients with a diagnosis of CRVO,BRVO or HRVO without macular edema 3. Duration of RVO not more than 4 months 4. Naïve patients. Patient with previous RVO (more than 12 months before the inclusion date) which completely resolved (normalization of visual acuity and fundus examination) and who experienced a recurrence of RVO are also considered naive 5. Patient who agrees to participate to the study and who has given his/her written, informed consent Exclusion Criteria: 1. Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period 2. Active or suspected ocular or periocular infection 3. Active severe intraocular inflammation 4. RVO complicated with neovascularization 5. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study eye 6. Patient already included in the study for the treatment of the fellow eye 7. Pregnant or breastfeeding woman 8. Lack of effective contraception for women of childbearing age 9. Patient taking part in an interventional study
Where this trial is running
Wuhan, Hubei
- Renmin Hospital of Wuhan University — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Renmin Hospital of Wuhan University — Renmin Hospital of Wuhan University
- Study coordinator: CZ Chen, PHD
- Email: whuchenchzh@163.com
- Phone: +86 13072765173
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.